RAP2C

RAP2C is a plasma membrane-localized Ras-family small GTPase that functions as a signaling node converting upstream GEF and cAMP inputs into control of cytoskeletal organization, MAPK activity, and cell fate decisions (PMID:16213650, PMID:23885123). Biochemically it binds GTP in a Mg2+-dependent manner and cycles between nucleotide states with slower GDP release and lower relative GTP affinity than Rap2B, and its C-terminal CAAX motif directs it to the plasma membrane (PMID:16213650). In epithelia, a JAM-A/ZO-2/afadin scaffold together with the exchange factor PDZ-GEF1 activates RAP2C, which then controls apical actomyosin contraction via RhoA and nonmuscle myosin phosphorylation to maintain paracellular barrier integrity (PMID:23885123). RAP2C also relays cAMP signaling through an EPAC1/2→RAP2C→MAP4K7→LATS1/2 cascade that phosphorylates YAP/TAZ to exclude them from the nucleus and restrain fibroblast proliferation, contraction, and ECM production (PMID:34046891). Across multiple cancer and disease cell types RAP2C activates MAPK/ERK signaling to promote proliferation and migration and suppress apoptosis, and it is a recurrent direct target of inhibitory microRNAs including miR-188-5p, miR-195, and miR-200c-3p (PMID:31541458, PMID:33302819, PMID:34676879). Additional roles include B-cell receptor–induced MTOC reorientation and F-actin remodeling (PMID:29457987), and an interaction with DRP1 that increases DRP1 S637 phosphorylation to modulate mitochondrial fusion and oxidative phosphorylation (PMID:36214632).

1. 2005 High

   Established RAP2C as a genuine GTP-binding Rap-family GTPase with distinct nucleotide-handling kinetics, defining its basic biochemical identity and membrane localization.

   Evidence In vitro GTP-binding and nucleotide exchange assays with recombinant protein plus subcellular localization in eukaryotic cells

   PMID:16213650

   Open questions at the time

   • No GEF or GAP partners identified in this work
   • Downstream effectors and cellular function not addressed
2. 2007 Medium

   Linked RAP2C overexpression to transcriptional output, providing an early hint of downstream signaling activity via SRE.

   Evidence SRE-luciferase reporter assay and overexpression localization in COS-7 cells

   PMID:17447155

   Open questions at the time

   • Single reporter readout without pathway dissection
   • Cytoplasmic localization on overexpression unexplained relative to membrane targeting
3. 2013 High

   Defined the upstream activating module (JAM-A/ZO-2/afadin/PDZ-GEF1) and a concrete epithelial function for RAP2C in barrier integrity through actomyosin contraction.

   Evidence Reciprocal Co-IP, multiple siRNA knockdowns with permeability and RhoA/myosin readouts, plus JAM-A-deficient mouse

   PMID:23885123

   Open questions at the time

   • Direct GEF action on RAP2C not reconstituted in vitro
   • Mechanism connecting RAP2C activation to RhoA not resolved
4. 2018 Medium

   Showed RAP2C drives cell motility independent of proliferation in osteosarcoma via MMP2/TIMP2 and Akt signaling.

   Evidence Gain/loss-of-function with Transwell assays, gelatin zymography, and western blot

   PMID:29552178

   Open questions at the time

   • Direct effectors linking RAP2C to Akt not identified
   • Single cell-line context
5. 2018 Medium

   Implicated RAP2C in immune cytoskeletal polarity by linking it to BCR-induced MTOC reorientation and F-actin remodeling.

   Evidence siRNA knockdown with microscopy-based MTOC and actin imaging in A20 B cells

   PMID:29457987

   Open questions at the time

   • Effector mediating MTOC reorientation unknown
   • GEF activating RAP2C in B cells not identified
6. 2020 Medium

   Established RAP2C as a MAPK-pathway activator controlling proliferation, migration, and apoptosis, and identified it as a direct target of tumor-suppressive miRNAs.

   Evidence Dual-luciferase miRNA target validation plus knockdown/overexpression with phenotypic and western readouts in breast and small cell lung cancer cells (and an in vivo tumor model)

   PMID:31541458 PMID:33302819

   Open questions at the time

   • Direct molecular link between RAP2C and MAPK kinases not defined
   • Whether GTP-loading state controls MAPK output untested
7. 2021 Medium

   Positioned RAP2C as an essential intermediate in a cAMP-driven Hippo cascade controlling YAP/TAZ localization and fibroblast behavior.

   Evidence Sequential siRNA epistasis (EPAC1/2→RAP2C→MAP4K7→LATS1/2) with YAP/TAZ localization and fibroblast functional assays

   PMID:34046891

   Open questions at the time

   • Direct RAP2C–MAP4K7 binding not demonstrated
   • Mechanism of cAMP/EPAC activation of RAP2C not reconstituted
8. 2021 Medium

   Extended RAP2C→ERK signaling to nucleus pulposus pathophysiology, linking it to apoptosis, inflammation, and ECM degradation.

   Evidence miRNA luciferase target validation, knockdown, and ERK inhibitor epistasis in LPS-treated NP cells

   PMID:34676879

   Open questions at the time

   • Direct effector coupling RAP2C to ERK unidentified
   • Single disease-cell context
9. 2022 Medium

   Revealed a non-canonical RAP2C role in mitochondrial dynamics via DRP1 interaction, regulated by the lncRNA LENOX.

   Evidence Co-IP of RAP2C–DRP1, DRP1 S637 phosphorylation, mitochondrial morphology and OXPHOS measurements, and combinatorial drug treatment in melanoma cells

   PMID:36214632

   Open questions at the time

   • Whether RAP2C directly phosphorylates or recruits a kinase to DRP1 unresolved
   • GTP-loading dependence of the DRP1 interaction untested
10. 2024 Medium

    Identified MAP4K4 as a direct RAP2C partner mediating MAPK-driven cardiomyocyte apoptosis under hypoxia/reoxygenation.

    Evidence Co-IP and co-immunofluorescence, double knockdown/overexpression epistasis, and apoptosis assays in H9C2 cells and rat I/R model (preprint)

    PMID:bio_10.1101_2024.12.04.626922

    Open questions at the time

    • Preprint, single lab, awaits peer review
    • Whether MAP4K4 is the general MAPK link across other RAP2C contexts unknown

• The GEF/GAP machinery and direct effector that couple RAP2C nucleotide state to MAPK/ERK activation across its many cellular contexts remain undefined.
• No unified structural or biochemical mechanism linking active RAP2C to specific MAP kinases
• Context-specificity determinants between barrier, Hippo, MAPK, and mitochondrial roles unknown